Efficacy and safety of eribulin mesylate vs. docetaxel or paclitaxel, combined with trastuzumab and pertuzumab, as first-line treatment for HER2-positive locally advanced or metastatic breast cancer: updated subgroup analyses of JBCRG-M06/EMERALD.

Saved in:
Bibliographic Details
Title: Efficacy and safety of eribulin mesylate vs. docetaxel or paclitaxel, combined with trastuzumab and pertuzumab, as first-line treatment for HER2-positive locally advanced or metastatic breast cancer: updated subgroup analyses of JBCRG-M06/EMERALD.
Authors: Masuda N; Department of Breast Surgery, Graduate School of Medicine, Kyoto University, 54 Shogoin-Kawahara-cho, Sakyo-ku, Kyoto, 606-8507, Japan. nmasuda@alpha.ocn.ne.jp., Saji S; Department of Medical Oncology, Fukushima Medical University, Fukushima, Japan., Kojima Y; Institute for Clinical Genetics and Genomics / Division of Breast Surgical Oncology, Department of Surgery, Showa Medical University, Tokyo, Japan., Kitada M; Department of Breast Disease Center, Asahikawa Medical University Hospital, Hokkaido, Japan., Tada H; Department of Surgery, Division of Breast and Endocrine Surgery, Tohoku University Graduate School of Medicine, Miyagi, Japan.; Division of Breast and Endocrine Surgery, Tohoku Medical and Pharmaceutical University, Miyagi, Japan., Iwasa T; Department of Medical Oncology, Kindai University Hospital, Osaka, Japan., Koizumi K; Department of Surgery 1, Division of Breast Surgery, Hamamatsu University School of Medicine, Shizuoka, Japan., Iwatani T; Department of Breast and Endocrine Surgery, St. Marianna University School of Medicine, Kanagawa, Japan., Sagara Y; Department of Breast and Thyroid Surgical Oncology, Social Medical Corporation Hakuaikai, Sagara Hospital, Kagoshima, Japan., Kuwayama T; Department of Breast Surgery, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Tokyo, Japan., Shimoda M; Department of Breast and Endocrine Surgery, Hyogo Medical University Hospital, Hyogo, Japan., Sasada T; Department of Breast and Endocrine Surgery, NHO Higashihiroshima Medical Center, Hiroshima, Japan., Tsugawa K; Department of Breast and Endocrine Surgery, St. Marianna University School of Medicine, Kanagawa, Japan., Kawaguchi Y; Department of Breast Surgery, Asahi University Hospital, Gifu, Japan., Shimomura A; Department of Breast and Medical Oncology, National Center for Global Health and Medicine, Tokyo, Japan., Yamaguchi T; Division of Biostatistics, Tohoku University Graduate School of Medicine, Miyagi, Japan., Hasegawa H; Medical HQs, Eisai Co., Ltd, Tokyo, Japan., Osaka S; Medical HQs, Eisai Co., Ltd, Tokyo, Japan., Morita S; Department of Biomedical Statistics and Bioinformatics, Graduate School of Medicine, Kyoto University, Kyoto, Japan., Yamashita T; Department of Breast Surgery and Oncology, Kanagawa Cancer Center, Kanagawa, Japan.
Source: Breast cancer research and treatment [Breast Cancer Res Treat] 2026 Jul 08; Vol. 218 (1). Date of Electronic Publication: 2026 Jul 08.
Publication Type: Journal Article; Randomized Controlled Trial; Multicenter Study; Clinical Trial, Phase III
Journal Info: Publisher: Kluwer Academic Country of Publication: Netherlands NLM ID: 8111104 Publication Model: Electronic Cited Medium: Internet ISSN: 1573-7217 (Electronic) Linking ISSN: 01676806 NLM ISO Abbreviation: Breast Cancer Res Treat Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1573-7217
DOI:10.1007/s10549-026-08004-5